Review of hormone-related issues after cancer immunotherapy
Official title: Immune Checkpoint Inhibitor Therapy- Induced Endocrinopathy and Metabolic Diseases -a Case Series of Taiwanese Patients
Run by National Taiwan University Hospital · NCT04079647 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study looks at how cancer immunotherapy may cause hormone and metabolic problems in patients to better understand these side effects and improve future care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years to 85 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | National Taiwan University Hospital Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Taipei) |
| Trial ID | NCT04079647 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients aged 20 and older who have received immunotherapy at NTUH and subsequently developed endocrinopathy.
✕Probably not a fit
Patients under 20 years old or those who are pregnant will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to analyze cases of patients who developed endocrinopathy and metabolic diseases following immunotherapy at National Taiwan University Hospital. It will involve a thorough review of patient data, including age, clinical presentation, imaging findings, and treatment responses. By statistically analyzing these cases, the study seeks to enhance understanding of the adverse effects associated with immune checkpoint inhibitors. Additionally, it will compare findings with existing literature to identify patterns and inform future management strategies.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and management of endocrinopathy in patients undergoing immunotherapy.
How similar studies have gone: While there is growing interest in the adverse effects of immunotherapy, this specific focus on endocrinopathy is relatively novel and has not been extensively studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who receive immunotherapy in NTUH and develop endocrinopathy after therapy Exclusion Criteria: * Patients less than 20 years old. Patients who are pregnant
Where it's running
-
Shyang-Rong Shih
Taipei, Taiwan Recruiting
Study contacts
- Study coordinator: Shyang-Rong Shih
- Email: srshih@ntu.edu.tw
- Phone: +886-972653337
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cohort of patients with plasma cell disorders at Peking University First Hospital
This study is looking at hospitalized patients with plasma cell disorders to see how their treatment and disease status affect their outcomes over time.
-
Registry for adults with plasma cell disorders
This study is creating a registry for adults with plasma cell disorders like multiple myeloma to track their health and care experiences over time while also collecting blood samples for future research.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.